BHP Attracts AI-Focused Investors as Copper Demand Surges 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
PARSIPPANY, N.J., May 01, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences:
- Deutsche Bank 43rd Annual Health Care Conference in Boston, on Wednesday, May 9 at 2:10 PM ET
- Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, on Tuesday, May 15, at 1:40 PM PT (4:40PM ET)
A live audio webcast of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcasts will be archived on the Pacira website for two weeks following the presentation dates.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Christian Pedetti (973) 254-4387 [email protected]
